Laxmi Dental Limited (LAXMIDENTL)

Healthcare · Healthcare Equipment & Supplies · NSE · Updated 15 August 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

₹201.82 ↓ 41.76% (1Y)

🎯 Key Takeaways

Laxmi Dental Limited is in a growth phase driven by product mix improvements and international demand, particularly in Dental Laboratory and Aligner Solutions segments. The company has demonstrated consistent top-line and margin expansion, supported by strategic investments in U.
⚠️ 1) The company operates in a capital-intensive healthcare equipment segment with long sales cycles, which may pressure near-term profitability. 2) Exp

Market Cap

₹1,105

P/E Ratio

57.2

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About LAXMIDENTL 📊 Interactive Charts

📖 The Story

Laxmi Dental Limited is in a growth phase driven by product mix improvements and international demand, particularly in Dental Laboratory and Aligner Solutions segments. The company has demonstrated consistent top-line and margin expansion, supported by strategic investments in U.S. leadership and AI automation, despite operating in a competitive healthcare equipment space.

📰 What's Happening

In Q1 FY27, Laxmi Dental reported consolidated revenue of ₹747.0 crores, up 13.9% YoY, with PAT rising 23.8% to ₹103.2 crores and EBITDA margin expanding to 19.2% from 18.2%. Management highlighted strong growth in Dental Laboratory (+23.5% YoY) and Aligner Solutions (+28.6% YoY), attributing it to improved product mix and international demand. The board approved land acquisition in Palghar and ESOP allotment of 59,360 shares under the 2024 scheme, signaling operational expansion. Additionally, ICRA confirmed no material deviations in IPO proceeds utilization, aligning with offer document disclosures.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q3FY25
Revenue	62
Operating Profit	10
OPM %	15.6%
Net Profit	5
EPS	₹0.88

The company has delivered sequential improvement in profitability, with EBITDA margin expanding to 19.2% in Q1 FY27 from prior periods, supported by higher-margin segments like Aligner Solutions. Revenue growth of 13.9% YoY in Q1 FY27 reflects successful market penetration and pricing power, particularly in international markets. Management attributes this trend to product mix optimization and automation investments, though no formal forward guidance was provided in the filing.

🔮 Management Outlook & What's Next

Management did not provide formal forward guidance in the Q1 FY27 financial results filing, focusing instead on operational momentum and strategic investments. The emphasis was on sustaining growth through U.S. market expansion and AI-driven automation, with no explicit revenue or margin targets disclosed. Capital allocation updates were limited to board-approved land acquisition and ESOP issuance without detailed timelines or ROI expectations.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Healthcare Equipment & Supplies

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Poly Medicure Limited	15,193	46.4	—	—	—
Fischer Medical Ventures Limited	2,261	59.0	—	—	—
Laxmi Dental Limited	1,105	57.2	—	—	—
Tarsons Products Limited	1,101	36.9	—	—	—
Fabtech Technologies Limited	681	—	—	—	—
Nureca Limited	260	-47.3	—	—	—

🔗 Peer Stock Analyses

POLYMED FISCHER TARSONS FABTECH NURECA

⚠️ Risk Factors

1) The company operates in a capital-intensive healthcare equipment segment with long sales cycles, which may pressure near-term profitability. 2) Expansion into new markets like the U.S. and land acquisition in Palghar introduces execution and regulatory risks without disclosed timelines or capital allocation details. 3) No forward guidance is provided, leaving investors without clarity on sustainability of margin expansion or growth trajectory.

📋 Recent Filings

🧠 Analyst's Read

Laxmi Dental is executing a growth strategy supported by strong segmental performance and margin improvement, but the lack of forward guidance and unclear capital deployment timelines introduces uncertainty. Investors should monitor upcoming investor presentations or earnings calls for strategic clarity on U.S. expansion and subsidiary merger progress.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on LAXMIDENTL

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-08-15.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when LAXMIDENTL files new disclosures

Track LAXMIDENTL filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track LAXMIDENTL — Free

Free account · 2 AI queries/day